Overview

Prognostic Predictors of Response to Hypoglycemic Therapy

Status:
Recruiting
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled trial aimed to determine highly specific personified predictors of response to the therapy by different groups of hypoglycemic drugs (SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas) in patients with type 2 diabetes mellitus, develop an algorithm of personalized therapy based on them, design an organizational and methodological model for prevention of the cardiovascular complications, and create an automated decision-making system for therapy selection to reduce the incidence of cardiovascular events and related adverse outcomes compared to the traditional approach. This is an interventional, randomized controlled trial, open-label study.
Phase:
Phase 4
Details
Lead Sponsor:
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Treatments:
Empagliflozin
Exenatide
Gliclazide
Glimepiride
Hypoglycemic Agents
Liraglutide
Sitagliptin Phosphate
Vildagliptin